Enarodustat is under clinical development by Japan Tobacco and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Enarodustat’s likelihood of approval (LoA) and phase transition for Anemia in Chronic Kidney Disease (Renal Anemia) took place on 04 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Enarodustat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Enarodustat overview

Enarodustat (Enaroy)  is a potent anti-anemic agent. It is formulated as film coated tablets for oral route of administration. Enaroy is indicated for the treatment of anemia associated with chronic kidney disease (CKD).

Enarodustat (JTZ-951) is under development for the treatment of anemia associated with chronic kidney disease. 

Japan Tobacco overview

Japan Tobacco (JT Group) is a tobacco company that manufactures cigarettes. It also manufactures, markets, and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread, and frozen bread, packaged cooked rice, bakery goods, yeast extracts and seasoning, prescription drugs, and generic drugs. The company distributes its products through supermarkets, street and train station kiosks, convenience stores, small independent retailers, and vending machines. JT Group caters to retail, industrial and commercial customers in Europe, Africa, the Middle East, Asia-Pacific, and the Americas, and other regions. The company manufactures its products in its own facilities in Japan and other countries. JT Group is headquartered in Minato-Ku, Tokyo, Japan.

Quick View Enarodustat LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Enarodustat
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.